Stocx Research Club logo ×
Screener Research Unlisted Startup Funding IPO

Alkem Laboratories

₹3408.5 -36.1 | 1%

Market Cap ₹40838 Cr.

Stock P/E 41.4

P/B 4.5

Current Price ₹3408.5

Book Value ₹ 756.5

Face Value 2

52W High ₹3624.8

Dividend Yield 1.46%

52W Low ₹ 2835.1

Alkem Laboratories Research see more...

Overview Inc. Year: 1973Industry: Pharmaceuticals & Drugs

Alkem Laboratories Limited is a pharmaceutical agency. The Company is engaged inside the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates via 2 segments: pharmaceutical and investing. The Company produces generics,generic drugs, APIs and neutraceuticals, which it markets in India and about 50 international locations across the world. The Company offers numerous products, which include CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, amongst others. The Company has approximately 16 production facilities, of which 14 manufacturing facilities are at geographically different places in India and within the United States.

Read More..

Alkem Laboratories Share Price

| |

Volume
Price

Quarterly Price

Show Value Show %

Alkem Laboratories Quarterly Results

#(Fig in Cr.) Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Net Sales 2318 2192 2731 2800 2619 2484 2576 3079 3041 2903
Other Income 96 46 47 42 54 21 51 51 45 69
Total Income 2414 2238 2778 2842 2673 2504 2628 3130 3086 2971
Total Expenditure 1789 1901 2139 2176 2121 2147 2373 2625 2442 2549
Operating Profit 626 337 640 666 552 358 255 505 644 422
Interest 13 11 13 12 11 17 27 25 27 29
Depreciation 69 69 71 73 77 83 76 77 78 78
Exceptional Income / Expenses 0 0 0 0 0 -15 0 0 0 -103
Profit Before Tax 543 258 556 582 464 243 152 402 539 212
Provision for Tax 80 9 76 23 -69 134 20 55 79 144
Profit After Tax 464 249 480 559 533 108 131 348 460 68
Adjustments -13 -9 -12 -14 -8 -1 -4 -17 -5 3
Profit After Adjustments 451 240 468 544 526 108 128 331 455 71
Adjusted Earnings Per Share 37.7 20.1 39.2 45.5 44 9 10.7 27.7 38 5.9

Alkem Laboratories Profit & Loss

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
Net Sales 2016 2495 3126 3743 4925 5688 6392 7357 8344 8865 10634 11599
Other Income 145 167 165 181 240 112 115 88 104 233 163 216
Total Income 2161 2662 3291 3924 5165 5800 6507 7445 8449 9098 10797 11815
Total Expenditure 1640 2133 2716 3322 4072 4689 5383 6242 6871 6923 8581 9989
Operating Profit 520 530 575 603 1093 1111 1124 1202 1578 2176 2216 1826
Interest 58 88 93 81 71 45 55 55 65 59 52 108
Depreciation 29 40 52 71 93 101 143 193 253 275 304 309
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 -15 -103
Profit Before Tax 433 402 430 451 928 965 926 955 1260 1842 1844 1305
Provision for Tax 28 18 -5 59 176 60 288 181 110 224 164 298
Profit After Tax 406 384 435 392 752 905 638 774 1149 1618 1680 1007
Adjustments 1 0 0 0 -11 -13 -7 -13 -22 -33 -35 -23
Profit After Adjustments 407 384 435 392 742 892 631 761 1127 1585 1646 985
Adjusted Earnings Per Share 34 32.1 36.4 32.8 62 74.6 52.8 63.6 94.3 132.6 137.7 82.3

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 20% 13% 13% 18%
Operating Profit CAGR 2% 23% 15% 16%
PAT CAGR 4% 29% 13% 15%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 9% 12% 12% NA%
ROE Average 21% 22% 19% 20%
ROCE Average 19% 20% 19% 18%

Alkem Laboratories Balance Sheet

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Shareholder's Funds 1820 2177 2585 2999 3692 4468 4864 5439 6161 7377 8638
Minority's Interest 0 0 0 86 95 115 122 133 148 181 209
Borrowings 309 256 232 33 123 182 131 231 74 28 9
Other Non-Current Liabilities 216 106 92 167 -430 -582 -489 -520 -614 -779 -902
Total Current Liabilities 1121 1732 1403 2006 1538 1690 2383 2218 3245 3604 4805
Total Liabilities 3466 4271 4311 5291 5018 5872 7010 7501 9013 10411 12760
Fixed Assets 919 1072 1170 1374 1450 1797 2284 2530 2908 2793 2902
Other Non-Current Assets 1234 1042 1539 1579 800 1158 713 754 599 690 1423
Total Current Assets 1312 2156 1602 2338 2769 2917 4013 4204 5506 6923 8434
Total Assets 3466 4271 4311 5291 5018 5872 7010 7501 9013 10411 12760

Alkem Laboratories Cash Flow

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Opening Cash & Cash Equivalents 124 26 57 101 124 127 167 167 249 176 174
Cash Flow from Operating Activities 159 78 290 325 726 471 266 780 585 1265 1111
Cash Flow from Investing Activities -248 -404 350 -237 202 -286 -357 -316 -741 -999 -1435
Cash Flow from Financing Activities -11 356 -600 -52 -927 -138 85 -379 79 -272 380
Net Cash Inflow / Outflow -100 30 41 37 1 47 -7 84 -77 -5 55
Closing Cash & Cash Equivalent 26 57 101 140 127 167 167 249 176 174 232

Alkem Laboratories Ratios

# Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Earnings Per Share (Rs) 33.99 32.09 36.4 32.76 62.03 74.62 52.78 63.61 94.28 132.58 137.65
CEPS(Rs) 36.36 35.4 40.77 38.69 70.73 84.14 65.37 80.87 117.28 158.29 165.98
DPS(Rs) 4 4 4 4 12.7 15 13 16 25 30 34
Book NAV/Share(Rs) 152.18 182.05 216.13 250.86 308.82 373.67 406.76 454.86 515.21 616.95 722.48
Core EBITDA Margin(%) 18.12 14.07 12.66 10.93 16.9 17.07 11.76 10.41 11.89 14.82 13.44
EBIT Margin(%) 23.73 19.02 16.15 13.78 19.8 17.25 11.43 9.42 10.69 14.5 12.42
Pre Tax Margin(%) 20.92 15.59 13.28 11.68 18.39 16.48 10.79 8.91 10.16 14.05 12.07
PAT Margin (%) 19.6 14.9 13.44 10.15 14.9 15.46 7.44 7.22 9.27 12.34 11
Cash Profit Margin (%) 21 16.44 15.06 11.98 16.75 17.19 9.1 9.03 11.31 14.43 12.99
ROA(%) 12.85 9.92 10.14 8.16 14.59 16.61 9.91 10.66 13.92 16.66 14.5
ROE(%) 24.95 19.19 18.28 14.03 22.48 22.18 13.69 15.02 19.82 23.91 20.99
ROCE(%) 19.02 14.96 14.06 13.27 23.1 21.31 17.86 16.49 18.71 22.56 18.69
Receivable days 36.8 40.02 38.62 42.27 39.57 39.95 38.15 39.69 42.66 45.33 41.72
Inventory Days 56.02 66.53 66.19 66.41 61.23 65.96 56.31 50.14 48.86 57.51 63.54
Payable days 125.4 118.68 92.7 96.89 117.1 133.45 156.37 135.69 118.18 118.18 114.79
PER(x) 0 0 0 0 22.03 29.58 37.46 27.54 24.7 20.91 26.28
Price/Book(x) 0 0 0 0 4.42 5.91 4.86 3.85 4.52 4.49 5.01
Dividend Yield(%) 0 0 0 0 0.93 0.68 0.66 0.91 1.07 1.08 0.94
EV/Net Sales(x) 0.25 0.23 0.3 0.14 3.29 4.68 3.76 2.88 3.4 3.71 4.07
EV/Core EBITDA(x) 0.97 1.07 1.62 0.89 14.83 23.98 21.4 17.65 17.98 15.1 19.52
Net Sales Growth(%) 19.21 23.79 25.28 19.75 31.56 15.49 12.38 15.1 13.42 6.24 19.96
EBIT Growth(%) 31.91 -0.33 6.78 1.7 87.93 1.01 -2.82 2.85 31.27 43.49 -0.23
PAT Growth(%) 37.21 -5.47 13.47 -10.05 92.1 20.27 -29.43 21.18 48.56 40.76 3.87
EPS Growth(%) 37.54 -5.59 13.42 -10.01 89.38 20.29 -29.27 20.54 48.2 40.63 3.82
Debt/Equity(x) 0.55 0.71 0.44 0.44 0.18 0.15 0.21 0.17 0.26 0.23 0.3
Current Ratio(x) 1.17 1.25 1.14 1.17 1.8 1.73 1.68 1.9 1.7 1.92 1.76
Quick Ratio(x) 0.83 0.93 0.7 0.77 1.21 1.01 1.08 1.22 1.14 1.28 1.13
Interest Cover(x) 8.46 5.55 5.62 6.56 14.03 22.36 17.74 18.48 20.36 32.26 36.22
Total Debt/Mcap(x) 0 0 0 0 0.04 0.02 0.04 0.05 0.06 0.05 0.06

Alkem Laboratories Shareholding Pattern

# Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
Promoter 62.43 60.16 58.84 58.84 57.13 57.13 57.14 57.16 57.16 57.16
FII 4.08 4.42 4.5 5.33 5.4 5.41 5.67 4.46 4.41 4.44
DII 12.96 13.2 14.49 13.99 13.94 14.14 14.1 15.74 16.44 16.69
Public 20.53 22.22 22.17 21.84 23.53 23.32 23.09 22.65 21.99 21.7
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 22%
  • Debtor days have improved from 118.18 to 114.79days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 4.5 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Alkem Laboratories News